Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.58 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4433275 | 0.85 | DAO (0.59) | DAOC3AR1PKMLIG1 | |
| SCHEMBL4430958 | 0.84 | DAO (0.53) | DAOC3AR1HPGDALDH1A1 | |
| SCHEMBL4438845 | 0.84 | DAO (0.53) | DAOC3AR1HPGDADRA2CMAOA | |
| SCHEMBL4439617 | 0.82 | DAO (0.51) | DAOC3AR1MEN1POLBRAB9A | |
| SCHEMBL4437601 | 0.82 | C3AR1 (0.54) | DAOC3AR1MEN1POLBRAB9A | |
| SCHEMBL4437624 | 0.78 | DAO (0.47) | DAOMEN1POLBKMT2AHPGD | |
| SCHEMBL4682575 | 0.78 | DAO (0.50) | DAOMEN1POLBRAB9AKMT2A | |
| SCHEMBL4432196 | 0.78 | DAO (0.50) | DAOMEN1POLBRAB9AKMT2A | |
| SCHEMBL4433269 | 0.77 | HDAC3 (0.49) | C3AR1MEN1POLBRAB9AKMT2A | |
| SCHEMBL4429555 | 0.77 | DAO (0.53) | DAOMEN1POLBRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776411-B1 | MODULATORS OF C3A RECEPTORS | UNIV QUEENSLAND (AU) | 2019-06-26 | — | — | EP | disclosed |
| US-9586914-B2 | Modulators of C3a receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-03-07 | — | — | US | disclosed |
| US-20140302069-A1 | MODULATORS OF C3A RECEPTORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-10-09 | — | — | US | disclosed |
| EP-2776411-A1 | MODULATORS OF C3A RECEPTORS | The University of Queensland (AU) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013067578-A1 | MODULATORS OF C3A RECEPTORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-05-16 | — | — | WO | disclosed |
| CN-101611008-A | C3A receptor modulators and methods of use thereof | ENCYSIVE PHARMACEUTICALS INC (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-2125739-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | DAO 1635/4885C3AR1 1/4885MEN1 2114/4885 |
| US-20140302069-A1 | MODULATORS OF C3A RECEPTORS | C3AR1, C5AR2, C5AR1 | DAO 2994/4885C3AR1 1/4885MEN1 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.